Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sells 5,985 Shares of Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sarepta Therapeutics Trading Down 0.5 %

Shares of SRPT stock opened at $135.10 on Wednesday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a 50-day simple moving average of $144.01 and a 200 day simple moving average of $133.14. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The stock has a market capitalization of $12.77 billion, a P/E ratio of 1,228.18 and a beta of 0.89.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter last year, the firm posted ($0.27) EPS. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on SRPT. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, August 15th. Oppenheimer upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price target for the company in a research report on Tuesday, May 14th. Leerink Partners lifted their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Cantor Fitzgerald reduced their target price on shares of Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Finally, Morgan Stanley restated an “overweight” rating and issued a $165.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $186.22.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Clearbridge Investments LLC boosted its stake in shares of Sarepta Therapeutics by 57.0% during the 2nd quarter. Clearbridge Investments LLC now owns 237,354 shares of the biotechnology company’s stock worth $37,502,000 after acquiring an additional 86,138 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $4,771,000. Cetera Investment Advisers lifted its holdings in shares of Sarepta Therapeutics by 8.5% during the second quarter. Cetera Investment Advisers now owns 13,013 shares of the biotechnology company’s stock valued at $2,056,000 after purchasing an additional 1,022 shares during the last quarter. Truist Financial Corp boosted its position in shares of Sarepta Therapeutics by 86.5% in the 2nd quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 1,857 shares during the period. Finally, EP Wealth Advisors LLC increased its stake in Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 103 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.